Skip to main content

Advertisement

A novel CD147 inhibitor, SP-8356, reduces neointimal hyperplasia and arterial stiffness in a rat model of partial carotid artery ligation

Journal of Translational Medicine volume 17, Article number: 274 (2019) Cite this article

  • 651 Accesses

Abstract

Background

Neointimal hyperplasia and its related arterial stiffness are the crucial pathophysiological features in atherosclerosis and in-stent restenosis. Cluster of differentiation 147 (CD147), a member of the immunoglobulin super family that induces the expression of matrix metalloproteinase-9 (MMP-9) by dimerization, may play important roles in neointimal hyperplasia and may therefore be an effective target for the treatment of this condition. Here, we investigated whether a novel CD147 inhibitor SP-8356 ((1S,5R)-4-(3,4-dihydroxy-5-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one) reduces neointimal hyperplasia and arterial stiffness in a rat model of partial carotid artery ligation.

Methods

Neointimal hyperplasia was induced in Sprague–Dawley rats by partial ligation of the right carotid artery combined with a high fat diet and vitamin D injection. Rats were subdivided into vehicle, SP-8356 (50 mg/kg), and rosuvastatin (10 mg/kg) groups. The drugs were administrated via intraperitoneal injections for 4 weeks. The elasticity of blood vessels was assessed by measuring pulse wave velocity using Doppler ultrasonography before sacrifice. Histomolecular analysis was carried out on harvested carotid arteries.

Results

SP-8356 significantly reduced MMP activity by inhibiting CD147 dimerization. SP-8356 reduced neointimal hyperplasia and prevented the deterioration of vascular elasticity. SP-8356 had a greater inhibitory effect on neointimal hyperplasia than did rosuvastatin. Furthermore, rosuvastatin did not improve vascular elasticity. SP-8356 increased the expression of smooth muscle myosin heavy chain (SM-MHC), but decreased the expression of collagen type III and MMP-9 in the neointimal region. In contrast to SP-8356, rosuvastatin did not alter the expression of SM-MHC or MMP-9.

Conclusions

The ability of SP-8356 to reduce neointimal hyperplasia and improve arterial stiffness in affected carotid artery suggests that SP-8356 could be a promising therapeutic drug for vascular remodeling disorders involving neointimal hyperplasia and arterial stiffness.

Background

Neointimal hyperplasia, defined as the thickening of the arterial intima with a narrowed arterial lumen space, is a key feature of early atherosclerotic lesions and in-stent restenosis [1, 2]. The key regulatory mechanism underlying neointimal hyperplasia is the phenotypic plasticity of vascular smooth muscle cells (VSMCs) [2]. In a normal physiologic state, most VSMCs in the blood vessels show contractile characteristics [2, 3]. However, exposure of the vessels to injury or inflammatory stimuli results in VSMC switching to a synthetic phenotype. These synthetic VSMCs migrate to the intima from the media and contribute to the formation of neointimal hyperplasia [4]. Furthermore, synthetic VSMCs in neointima accelerate lipid deposition and macrophage chemotaxis, leading to the progression of atherosclerosis [1, 5]. Thus, synthetic VSMCs not only build up neointima but may also promote plaque vulnerability.

Neointimal hyperplasia is composed of migrated synthetic VSMCs with lower amounts of contractile proteins and higher amounts of extracellular matrix (ECM) components [2]. These changes in vascular smooth muscle tone and ECM components contribute to arterial stiffening [6]. Arterial stiffness has been regarded as an important predictor of future cardiovascular events and all-cause mortality [7]. Therefore, attenuation of neointimal hyperplasia may be an important therapeutic target for patients with vascular remodeling disorders, including atherosclerosis and in-stent restenosis.

Matrix metalloproteinases (MMPs) have been regarded as a key player in VSMC migration [8, 9]. MMPs are proteolytic enzymes that cleave ECM and modulate chemokines. Chemokines, in turn, facilitate the easy migration of VSMCs to neointima and initiate synthetic VSMC activities [8]. Among the various MMPs, particularly, overexpression of MMP-9 is well known to enhance VSMC migration with synthetic properties [8, 9]. MMP expression can be induced by cluster of differentiation 147 (CD147), which is located on the VSMCs [10]. CD147, also known as extracellular MMP inducer (EMMPRIN), is a cell surface glycoprotein that induces MMP expression [11,12,13] by homophilic interactions such as dimerization [13, 14].

We recently reported that a series of (1S)-(-)-verbenone derivatives exhibited cytoprotective activities [15] and found that certain (1S)-(-)-verbenone derivatives in an in-house chemical library inhibited cerebral hemorrhage by inhibiting MMP activity (unpublished results). One of these (1S)-(-)-verbenone derivatives, (1S,5R)-4-(3,4-dihydroxy-5-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (SP-8356), was found most effective in reducing MMP activity by inhibiting CD147 dimerization. Recently, we and others reported that partial carotid artery ligation induced neointimal hyperplasia in rats fed a high fat diet [16, 17]. The present study investigated the ability of SP-8356 to inhibit VSMC migration and arterial stiffness in this rat model characterized by neointimal hyperplasia.

Methods

Non-denaturing sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) assays

Recombinant human CD147 protein (5 μg/mL, ab155636, Abcam, Cambridge, MA, USA) was added to various concentrations of SP-8356 and mixed with sample buffer lacking SDS, followed by resolution by 10% SDS-PAGE without boiling. Anti-CD147 antibody (ab108317, Abcam, Cambridge, MA, USA) was used for immunoblotting. The concentration of recombinant human CD147 protein was determined following the previous study which reported the inhibitory effect of AC-73 on CD 147 dimerization [18].

Surface plasmon resonance (SPR) assays

SPR assays were performed on an SR7500DC instrument (Reichert Inc., Buffalo, NY, USA) at 25 °C. Approximately 4000 resonance units (RU) of recombinant human CD147 (ab155636, Abcam), at a concentration of 3 μg/mL in 10 mmol/L sodium acetate (pH 4.5), were immobilized on CMDH chips containing gold (Reichert Inc., Buffalo, NY, USA), using the amine coupling kit supplied by the manufacturer. The analyte (SP-8356; 300.35 kDa) was dissolved in running buffer (1X PBS, 2% DMSO, pH 7.4) and injected over the flow cells at concentrations of 6.25, 12.5, 25, 50, 100, 200 and 400 μM, in that order, at a flow rate of 30 μL/min. As a control, 1.25–640 nM anti-CD147 antibody (ab108317, Abcam), from lowest to highest concentration, was injected over the flow cells to test its binding to immobilized CD147. The association and dissociation times were both 5 min. After each round, the surface of the sensor chip was regenerated by injection of NaOH (5–50 mM) for 1 min until the RU signal returned the baseline. An equilibrium dissociation rate constant (Kd) was calculated from the kinetic rate constants by a simple 1:1 interaction model using Scrubber 2 software (Biologic Software, Campbell, Australia).

Cell culture

The A10 vascular smooth muscle cell line (ATCC CRL 1476) was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were cultured in Dulbecco’s modified eagle medium (DMEM; Welgene, Daegu, Korea) supplemented with 10% fetal bovine serum (FBS; HyClone, Logan, UT, USA), and 1% penicillin/streptomycin (HyClone) at 37 °C in a 5% CO2 humidified atmosphere. The contractile type of VSMC was induced by serum deprivation for 6 days [19].

Immunocytochemistry

To assess whether SP-8356 affects VSCM phenotype modulation, induced contractile VSMCs were pre-treated with SP-8356 for 30 min and subsequently treated with recombinant human protein CD147 (5 μg/mL, ab155636, Abcam, Cambridge, MA, USA). After 24 h of incubation, cells were washed with phosphate-buffered saline and fixed with 4% paraformaldehyde. Cells were then permeabilized with 0.3% Triton X-100 and blocked for 30 min with 1% bovine serum albumin in PBST, followed by incubated at 4 °C with primary antibody to smooth muscle myosin heavy chain (SM-MHC) (1:200 dilution, ab683, Abcam, Cambridge, MA, USA) for overnight. Alexa Fluor 488-conjugated goat anti-mouse IgG (1:400 dilution, A28175, Invitrogen, Carlsbad, CA, USA) was used for secondary antibody and nuclei were stained with Hoechst 33,342 solution.

Gelatin zymography

MMP activities of cultured VMSCs were evaluated by gelatin zymography. A10 VSMCs were treated for 24 h with SP-8356 in the presence of recombinant human protein CD147 (5 μg/mL, ab155636, Abcam, Cambridge, MA, USA). Conditioned media were collected and centrifuged to remove cellular debris and concentrated by Microcon centrifugal filtration (Millipore, Billerica, MA, USA). These samples were mixed with a non-reducing loading buffer without heating and loaded onto 10% SDS-PAGE gels containing 1 mg/mL gelatin (JT Baker Chemical Co., Phillipsburg, NJ, USA). Proteins were separated by electrophoresis at 125 V for 90 min. A MMP-9 recombinant protein (ab168863, Abcam, Cambridge, MA, USA) was loaded as a positive control. Following electrophoresis, the gels were rinsed twice for 30 min with Novex zymography renaturing buffer (Invitrogen, Carlsbad, CA, USA), incubated overnight with Zymogram developing buffer (Invitrogen), and stained with a Simply Blue Safe Stain (Invitrogen).

Migration assay

VSMC migration assays were performed with 24-well Transwell plates and polycarbonate membranes (8-μm pore size, Costar, Corning, NY, USA) coated with Matrigel (Sigma, St Louis, MO, USA). The upper chambers were seeded with 1.5 × 105 VSMCs in 200 μL serum-free DMEM. The Transwells were placed in 24-well culture dishes in 800 μL serum-free DMEM. After incubation for 12 h with SP-8356 in the presence of recombinant human CD147 (5 μg/mL, ab155636), the membranes were fixed and stained with a Hemacolor rapid staining kit (Merck, Darmstadt, Germany). The number of cells that had migrated to the lower chambers was counted (5 random fields/membrane) using an inverted microscope (Leica DM IL, Leica Microsystems, Wetzlar, Germany).

Animals

Male Sprague–Dawley rats (7 weeks old, 200–250 g body weight) were purchased from Orient-Bio (Seongnam, Korea). All rats were housed under a 12-h light/dark cycle with ad libitum access to water and food.

Induction of neointimal hyperplasia

After the rats were acclimated for 1 week, they were subjected to partial right carotid artery ligation, as described [17, 20]. In brief, anesthesia was initiated with 3.5% isoflurane in a 2:1 N2O/O2 mixture in a vented anesthesia chamber and sustained by inhalation through a nasal cone of 2 to 2.5% isoflurane in a 2:1 N2O/O2 mixture. The right external carotid artery, occipital artery and right internal carotid artery were ligated with 6-0 silk sutures, followed by intraperitoneal injection of vitamin D3 (6 × 105 IU/kg) once daily for 2 days. Vitamin D3 is often used to stimulate VSMC proliferation and migration [21, 22]. All rats were fed with a commercially available high fat diet (D12336, Research Diets, NJ, USA) for 1 month (28 days).

Drug treatment

The day after their last vitamin D injection, the rats were subdivided into three groups. The rats were injected intraperitoneally with vehicle (0.9% normal saline), rosuvastatin (10 mg/kg in saline, used as a reference drug) or SP-8356 (50 mg/kg in saline) once daily for 4 weeks. Rosuvastatin is a hydroxymethylglutaryl coenzyme A reductase inhibitor that has been well known to reduce neointima formation in animal models [23,24,25]. Statins also reduce restenosis characterized by neointimal hyperplasia after coronary stent implantation in clinical studies [26, 27]. At doses of 1, 10, and 20 mg/kg, rosuvastatin was reported to inhibit neointimal hyperplasia [23,24,25]. At a dose of 80 mg/kg, simvastatin has been known to be toxic to VSMCs [28], and recently it was reported that 20 mg/kg of rosuvastatin is equivalent to 80 mg/kg of simavastatin [29]. Therefore, we treated rats with 10 mg/kg of rosuvastatin. The in vivo therapeutic dose of SP-8356 corresponding to in vitro dose was determined based on our previous pharmacokinetic-pharmacodynamic relationship study [30].

Pulse wave velocity (PWV) measurement

After 4 weeks of drug administration, PWV was measured using an ultrasound Doppler system (iU22, Philips Ultrasound, Bothell, WA, USA). Electrocardiography limb electrodes were placed and the Doppler probe was located parallel to the blood flow of the right carotid and left iliac arteries. The electrocardiography and Doppler signals were recorded simultaneously; the distance and time were defined as described previously [31]. Distance was measured between the site probe points over the carotid and iliac arteries, and the time was measured between the R peak waves of the electrocardiogram to the foot of the carotid or iliac wave signals. The times were averaged over three consecutive electrocardiography cycles. PWV (m/s) was calculated as:

$$ {\text{PWV }}\left( {{\text{m}}/{\text{s}}} \right) = \frac{\text{Distance from carotid to iliac artery}}{{{\text{Time }}\left( {{\text{R peak point to iliac foot}} - {\text{R peak point to carotid foot}}} \right)}} $$

Blood pressure

Blood pressure was measured using a tail-cuff method (ML125, Powerlab, AD Instruments, Castle Hill, NSW, Australia). Rats were placed in a chamber pre-heated to 35 °C for 10 min and moved to plastic restrainers. To obtain accurate and reliable blood pressure result, rats were handled gently and not forced to enter plastic restrainer. Rats remained stable and unperturbed during the measurement period. A cuff with a pneumatic sensor was applied onto the tail and blood pressure was measured, with the results averaged from three consecutive recordings.

Histopathology

All rats survived during the study period and were sacrificed by carbon dioxide inhalation after 4 weeks of drug administration. The common carotid arteries were fixed with 4% paraformaldehyde and preserved in 30% sucrose solution. The tissue was embedded in optimal cutting temperature compound (Scigen Scientific, Gardena, CA, USA). Axial sections of 4 μm thickness were cut with a cryostat microtome (Leica CM 3050 S, Leica Microsystems). Serial sections were obtained down-stream of the bifurcation of the external and internal carotid arteries. In accordance with the guidelines for experimental study of vessel by the American Heart Association [32], lesions were analyzed in a blinded manner and quantified as an average of 6 serial sections, each 100 μm apart from each other. The sections were stained with hematoxylin and eosin and evaluated using an upright light microscope (BX51, Olympus, Tokyo, Japan). The neointimal area was defined as the area between the luminal circumference and the internal elastic lamina. The media area was defined as the area between the internal and external elastic lamina. The neointima/media ratio was defined as the area of the neointima divided by the area of the media.

Immunohistochemistry

Sections were blocked for 60 min with 5% goat serum in phosphate-buffered saline containing 0.1% Triton X-100, and incubated at 4 °C with primary antibodies to α-smooth muscle-actin (α-SMA) (1:200 dilution, ab7817, Abcam, Cambridge, MA, USA), SM-MHC (1:200 dilution, ab683, Abcam, Cambridge, MA, USA), MMP-9 (1:200 dilution, AB19016, Merck Millipore, Billerica, MA, USA), and collagen type III (1:200 dilution, ab7778, Abcam, Cambridge, MA, USA). The sections were washed and incubated with the appropriate secondary antibody, Alexa Fluor 555-conjugated goat anti-mouse IgG (1:400 dilution, A21424, Invitrogen, Carlsbad, CA, USA) or Alexa Fluor 488-conjugated goat anti-rabbit IgG (1:400 dilution, A11034, Invitrogen, Carlsbad, CA, USA), followed by counterstaining of the nuclei with 4′, 6-diamidino-2-phenylindole (DAPI). All images were obtained using a confocal microscope (LSM800, Carl Zeiss, Oberkochen, Germany).

Molecular expression intensity in the neointimal area was analyzed using Image J version 1.45 s open-source software (NIH Image, Bethesda, MD, USA). A region of interest (ROI) was drawn on the neointimal area and the integrated density of pixels in the ROI was calculated. The intensity/area ratio was calculated as the integrated density divided by the area of the neointima. Unstained and secondary antibody stained control images of neointimal hyperplasia were shown in Additional file 1: Figure S1.

Statistical analysis

All data were presented as the mean ± standard deviation of at least three independent experiments. Multiple groups were compared by one-way analysis of variance (ANOVA) followed by post hoc Tukey’s test and two groups were compared by Student’s t test. All statistical analyses were performed using SPSS version 17.0 software (SPSS Inc, Chicago, IL, USA), with a p-value < 0.05 considered statistically significant.

Results

SP-8356 disrupts the dimerization of CD147

Dimerization of CD147 induces MMP expression and activation [14]. To identify compounds that could disrupt CD147 dimerization, we screened our in-house chemical library [15], finding that SP-8356 inhibited CD147 dimerization in a concentration-dependent manner (Fig. 1a–c).

Fig. 1
figure1

Discovery and activity of SP-8356. a Screening strategy. b Structure of SP-8356. c Representative image and quantitative analysis of CD147 dimerization. Data are presented as the mean ± standard deviation (SD) of three independent experiments. *p < 0.05 vs. vehicle. d Surface plasmon resonance (SPR) assay of anti-CD147 antibody, AC-73, and SP-8356 with CD147

Full size image

SP-8356 binds to CD147

Surface plasmon resonance (SPR) is an optical technique utilized for detecting molecular interactions [33]. We have utilized SPR to study the specific binding of SP-8356 with CD147. As shown in Fig. 1d, SP-8356 exhibited 3 times lower equilibrium dissociation constant (i.e., higher affinity) than that of AC-73, a previously described CD147 inhibitor [18].

SP-8356 enhances the contractile phenotype expression in cultured VSMCs

As shown in Fig. 2a, b, VSMCs cultured in serum-deprived condition showed increased expression of SM-MHC, which was reduced by treatment with recombinant CD147. SP-8356 reversed the recombinant CD147-induced reduction of SM-MHC expression.

Fig. 2
figure2

SP-8356 enhances the contractile phenotype expression and attenuates CD147-stimulated matrix metalloproteinase-9 (MMP-9) activation in vascular smooth muscle cells (VSMCs) and CD147-induced VSMC migration. a Representative images of immunocytochemistry and b quantitative analysis of relative smooth muscle myosin heavy chain (SM-MHC) expression. Scale bar, 100 μm. Magnification, × 100. Data are presented as the mean ± SD of three independent experiments. ### p < 0.001 vs. control without CD147 treatment. *p < 0.05, ***p < 0.001 vs. CD147 treatment alone. c Representative images of gelatin zymography and quantitative analysis of active MMP-9 level. Data are presented as the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control. d Representative image of VSMC migration and quantitative analysis. Scale bar, 100 μm. Magnification, × 100. Data are presented as the mean ± SD of three independent experiments. ## p < 0.01 vs. control without CD147 stimulation. *p < 0.05, **p < 0.01, ***p < 0.001 vs. CD147 stimulation alone

Full size image

SP-8356 reduces CD147-evoked MMP and migratory activity in cultured VSMCs

A10 cells are undifferentiated VSMCs that differ from neonatal but show significant similarity to neointimal cells [34]. Thus, A10 cells have been commonly used as a model of synthetic VSMCs in neointimal hyperplasia. Gelatin zymography showed that treatment with recombinant CD147 increased MMP-9 activity in cultured VSMCs (Fig. 2c), which was inhibited by SP-8356 in a concentration dependent manner. Matrigel that is composed of basement membrane extracts has widespread use in cell migration assays [35]. Thus, as MMP-9 up-regulation is well known to promote VSMC migration [8, 9], we further performed Matrigel assays to test whether SP-8356 inhibits VSMC migration. In Matrigel assays, treatment with recombinant CD147 stimulated the migration of VSMCs (Fig. 2d), which was inhibited by SP-8356 in a concentration dependent manner.

SP-8356 attenuates neointimal hyperplasia and improves arterial stiffness

While the normal artery presented little intima, the affected right carotid artery presented prominent luminal narrowing with neointimal hyperplasia (Fig. 3a). Both SP-8356 and rosuvastatin reduced neointimal hyperplasia (Fig. 3a). When neointimal hyperplasia was measured as the ratio of neointima to media, however, we found that SP-8356 reduced neointimal hyperplasia to a greater extent than rosuvastatin (Fig. 3b). Arterial stiffness assessed by measuring PWV was higher in rats with neointimal hyperplasia than in normal rats (Fig. 3c). SP-8356 reduced the aggravated arterial stiffness in rats fed a high fat/vitamin D diet (Fig. 3c). Despite its suppression of neointimal hyperplasia, however, rosuvastatin did not reduce the PWV elevated by neointimal hyperplasia (Fig. 3c).

Fig. 3
figure3

SP-8356 inhibits neointimal hyperplasia and prevents arterial stiffness. a Representative cross-sections of carotid arteries stained with hematoxylin–eosin (H&E). Scale bar, 100 μm. Magnification, × 100. b Ratios of neointima and media areas. Vehicle (n = 9), rosuvastatin (n = 6), and SP-8356 (n = 9). Data are presented as a box plot ± range. **p < 0.01, ***p < 0.001. c Arterial stiffness was assessed by measuring pulse wave velocity (PWV). Normal (n = 15), vehicle (n = 9), rosuvastatin (n = 6), and SP-8356 (n = 6). Data are presented as box plot ± range. *p < 0.05, **p < 0.01, ***p < 0.001

Full size image

There were no statistically significant differences among the normal, vehicle, and SP-8356 groups in systolic (128.39 ± 8.38 mmHg vs. 137.29 ± 8.38 mmHg vs. 134.33 ± 11.17 mmHg, p = 0.091) and diastolic (81.85 ± 8.46 mmHg vs. 87.17 ± 9.68 mmHg vs. 87.58 ± 10.92 mmHg, p = 0.448) blood pressure. These findings indicate that arterial stiffness was not influenced by blood pressure during or after SP-8356 treatment or experimental procedures.

SP-8356 reduces MMP-9 expression and synthetic VSMC activity in neointima

MMP-9 was abundantly expressed in proliferative neointima, which was significantly reduced by SP-8356 (Fig. 4a, b). In contrast, rosuvastatin treatment had no effect on MMP-9 expression (Fig. 4a, b). Because MMP-9 promotes synthetic VSMC characteristics [8], we studied the effects of SP-8356 treatment on VSMC characteristics. SP-8356 significantly increased the expression of SM-MHC (Fig. 4c, d) and reduced the expression of collagen type III (Fig. 5a, b), but did not significantly alter the expression of α-SMA (Fig. 5c, d). In contrast, rosuvastatin did not increase the expression of SM-MHC in affected carotid arteries (Fig. 4c, d).

Fig. 4
figure4

SP-8356 reduces MMP-9 expression and enhances SM-MHC. a Representative image of MMP-9 expression. Vehicle (n = 9), rosuvastatin (n = 6) and SP-8356 (n = 9). The nuclei were stained with DAPI. Scale bars, 100 μm. Magnification, × 100. b Quantification of MMP-9 expression. Data are presented as box plot ± range. *p < 0.05. c Representative image of SM-MHC expression. Vehicle (n = 9), rosuvastatin (n = 6) and SP-8356 (n = 9). The nuclei were stained with DAPI. Scale bars, 100 µm. Magnification, × 100. d Quantification of SM-MHC expression. Data are presented as box plot ± range. **p < 0.01, ***p < 0.001

Full size image
Fig. 5
figure5

Down-regulation of collagen type III by SP-8356. a Representative image of collagen type III expression. Vehicle (n = 9) and SP-8356 (n = 9). Scale bars, 100 μm. Magnification, × 100. b Quantification of collagen type III expression. Data are presented as box plot ± range. **p < 0.01. c Representative image of α-smooth muscle-actin (α-SMA) expression. Vehicle (n = 9) and SP-8356 (n = 9). The nuclei were stained with DAPI. Scale bars, 100 μm. Magnification, × 100. (D) Quantification of α-SMA expression. Data are presented as box plot ± range. n.s.: not significant

Full size image

Discussion

CD147 is expressed in normal blood vessels, but its expression is higher under pathological conditions, during which CD147 may contribute to ECM remodeling by up-regulating MMP expression. The present study showed that a novel drug SP-8356 directly inhibited CD147 dimerization, suggesting that inhibition of the CD147-MMP pathway by SP-8356 may reduce neointimal hyperplasia in injured arteries and improve arterial stiffness.

MMP has been shown to promote VSMC migration, thereby contributing to neointimal hyperplasia [36]. Inhibition of MMP-9 expression by gene modulation was reported to reduce both VSMC migration and neointima formation [37, 38]. MMP also promotes synthetic properties of VSMCs [8], resulting in the deterioration of arterial stiffness [6]. In the present study, we found that SP-8356 elevated the level of SM-MHC and suppressed that of collagen type III, both of which could contribute to an improvement in arterial stiffness [6]. Similar to SP-8356, rosuvastatin was reported to reduce VSMC proliferation [23,24,25]. Unlike SP-8356, however, rosuvastatin did not improve arterial stiffness. The differing effects of SP-8356 and rosuvastatin on arterial stiffness may be due to differences in their regulation of MMP and SM-MHC expression. Our findings are in agreement with results showing that rosuvastatin inhibited neointimal hyperplasia via an MMP-9 independent mechanism [25, 39]. Furthermore, a high dose (80 mg/kg) of simvastatin was found to induce VSMC contractile dysfunction and to be toxic to VSMCs in rat models [28].

Although both SM-MHC and α-SMA reflect contractile properties of VSMCs [3], α-SMA is expressed by both synthetic and contractile VSMCs, whereas SM-MHC is expressed only by contractile VSMCs [2]. Thus, SM-MHC may be a more reliable marker of contractile VSMCs. Although SM-MHC expression in intimal VSMCs was found to be reduced during neointimal hyperplasia, α-SMA expression was preserved [2, 17, 40, 41]. Our experimental model also showed that SM-MHC expression was reduced, whereas α-SMA was unaltered, in neointima. Thus, the up-regulation of SM-MHC expression may contribute to the preservation of arterial elasticity in rats treated with SP-8356.

VSMC plasticity plays crucial roles in in-stent restenosis as well as atherosclerosis [4]. Revascularization by angioplasty/stenting is a common and effective treatment to restore blood flow in narrowed or blocked atherosclerotic lesions. In-stent restenosis, however, is a frequent complication of stent implantation, occurring in 15–60% of patients [42], and is thought to result from neointimal hyperplasia caused by synthetic VSMC activation. Thus, synthetic VSMCs are attractive therapeutic targets to inhibit neointimal proliferation after tenting [4]. In-stent restenosis may be prevented by implantation of drug-eluting-stents (DES) containing anti-proliferative drugs such as sirolimus and paclitaxel. These drugs inhibit the proliferation of VSMCs by targeting the mechanistic target of rapamycin (mTOR) or microtubule assembly [43, 44]. However, these DESs can elicit late thrombosis by the attenuation of re-endothelization through endothelial toxicity [22, 45] and even increase the long-term risk of death compared with bare-metal stents after 6 months [45]. There is a pressing need for new drugs that inhibit restenosis for successful revascularization without late thrombosis. The results of the present study suggest that SP-8356 may be a promising new drug to inhibit in-stent restenosis.

Neointimal hyperplasia with VSMC activation involves complex multifactorial pathophysiology including inflammation and oxidative stress [46, 47]. MMP-9 modulation via its interaction with CD147 may not be the sole explanation for the vasoprotective effect of SP-8356. SP-8356 was designed to function as a multi-target directed drug with anti-inflammatory and anti-oxidative properties [15, 48]. Thus, the pleiotropic effects of SP-8356 may also contribute to the vasoprotective effects of SP-8356.

This study used a rat model of partial carotid artery ligation to evaluate the arteries with pathological remodeling. This model closely resembles the pathophysiologic hemodynamic features of atherosclerosis in humans, including low shear stress, which contribute to the formation of neointimal hyperplasia [20]. This model is therefore suitable for the evaluation of vascular remodeling disorders, in which synthetic VSMC migration is the main pathologic feature. This rat model, however, has limitations, including its inability to mimic the plaque vulnerability, rupture, and thrombosis found in advanced atherosclerotic lesions [20]. Other models of advanced atherosclerotic lesions, such as apolipoprotein E knock-out mice, are needed to fully assess the anti-atherosclerotic activities of SP-8356.

Although SP-8356 effectively reduced MMP activity by inhibiting CD147 dimerization in in vitro experimental methods, it may also have other off-target binding effects in addition to CD147. For example, CD147 increases MMP activity through binding with cyclophilin A [10], which may also be inhibited by SP-8356. Therefore, further studies on the target profile of SP-8356 are needed.

Conclusions

This study provides strong evidence that SP-8356 can inhibit neointimal hyperplasia and improve arterial stiffness in a rat model of partial carotid artery ligation. Although its full mechanism remains to be determined, SP-8356 exhibits vasoprotective effects, probably by disrupting CD147 dimerization and thereby suppressing MMP-9 expression. SP-8356 may be a promising therapeutic drug for the treatment of vascular remodeling disorders.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Abbreviations

CD147:

cluster of differentiation 147

VSMC:

vascular smooth muscle cell

ECM:

extracellular matrix

MMP:

matrix metalloproteinase

SPR:

surface plasmon resonance

PWV:

pulse wave velocity

α-SMA:

α-smooth muscle-actin

SM-MHC:

smooth muscle myosin heavy chain

DES:

drug-eluting-stents

References

  1. 1.

    Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med. 2002;8:1249–56.

  2. 2.

    Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767–801.

  3. 3.

    Rensen SS, Doevendans PA, van Eys GJ. Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J. 2007;15:100–8.

  4. 4.

    Cai Y, Knight WE, Guo S, Li JD, Knight PA, Yan C. Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration. J Pharmacol Exp Ther. 2012;343:479–88.

  5. 5.

    Subbotin VM. Excessive intimal hyperplasia in human coronary arteries before intimal lipid depositions is the initiation of coronary atherosclerosis and constitutes a therapeutic target. Drug Discov Today. 2016;21:1578–95.

  6. 6.

    Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25:932–43.

  7. 7.

    Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systemic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318–27.

  8. 8.

    Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res. 2006;9:614–24.

  9. 9.

    Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251–62.

  10. 10.

    Seizer P, Gawaz M, May AE. Cyclophilin A and EMMPRIN (CD147) in cardiovascular diseases. Cardiovasc Res. 2014;102:17–23.

  11. 11.

    Major TC, Liang L, Lu X, Rosebury W, Bocan TM. Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol. 2002;22:1200–7.

  12. 12.

    Xiong L, Edwards CK 3rd, Zhou L. The biological function and clinical utilization of CD147 in human disease: a review of the current scientific literature. Int J Mol Sci. 2014;15:17411–41.

  13. 13.

    Grass GD, Toole BP. How, with whom and when: an overview of CD147-mediated regulatory networks influencing matrix metalloproteinase activity. Biosci Rep. 2015;36:e00283.

  14. 14.

    Schlegel J, Redzic JC, Porter CC, Yurchenko V, Bukrinsky M, Labeikovsky W, Armstrong GS, Zhang F, Isern NG, DeGregori J, et al. Solution characterization of the extracellular region of CD147 and its interaction with its enzyme ligand cyclophilin A. J Mol Biol. 2009;391:518–35.

  15. 15.

    Ju C, Song S, Hwang S, Kim C, Kim M, Gu J, Oh YK, Lee K, Kwon J, Lee K, et al. Discovery of novel (1S)-(-)-verbenone derivatives with anti-oxidant and anti-ischemic effects. Bioorg Med Chem Lett. 2013;23:5421–5.

  16. 16.

    Wei S, Zhang Y, Su L, He K, Wang Q, Zhang Y, Yang D, Yang Y, Ma S. Apolipoprotein E-deficient rats develop atherosclerotic plaques in partially ligated carotid arteries. Atherosclerosis. 2015;243:589–92.

  17. 17.

    Pahk K, Joung C, Jung SM, Young Song H, Yong Park J, Woo Byun J, Lee YS, Chul Paeng J, Kim C, Kim S, et al. Visualization of synthetic vascular smooth muscle cells in atherosclerotic carotid arteries by F-18 FDG PET. Sci Rep. 2017;7:6989.

  18. 18.

    Fu ZG, Wang L, Cui HY, Peng JL, Wang SJ, Geng JJ, Liu JD, Feng F, Song F, Li L, et al. A Novel small-molecular compound targeting CD147 inhibits the motility and invasion of hepatocellular carcinoma cells. Oncotarget. 2016;7:9429–47.

  19. 19.

    Li S, Sims S, Jiao Y, Chow LH, Pickering JG. Evidence from a novel human cell clone that adult vascular smooth muscle cells can convert reversibly between noncontractile and contractile phenotypes. Circ Res. 1999;85:338–48.

  20. 20.

    Winkel LC, Hoogendoorn A, Xing R, Wentzel JJ, Van der Heiden K. Animal models of surgically manipulated flow velocities to study shear stress-induced atherosclerosis. Atherosclerosis. 2015;241:100–10.

  21. 21.

    Cardús A, Parisi E, Gallego C, Aldea M, Fernández E, Valdivielso JM. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int. 2006;69:1377–84.

  22. 22.

    Rebsamen MC, Sun J, Norman AW, Liao JK. 1alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res. 2002;91:17–24.

  23. 23.

    Werner N, Priller J, Laufs U, Endres M, Böhm M, Dirnagl U, Nickenig G. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation. Arterioscler Thromb Vasc Biol. 2002;22:1567–72.

  24. 24.

    Schäfer K, Kaiser K, Konstantinides S. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury. Thromb Haemost. 2005;93:145–52.

  25. 25.

    Preusch MR, Vanakaris A, Bea F, Ieronimakis N, Shimizu T, Konstandin M, Morris-Rosenfeld S, Albrecht C, Kranzhöfer A, Katus HA, et al. Rosuvastatin reduces neointima formation in a rat model of balloon injury. Eur J Med Res. 2010;15:461–7.

  26. 26.

    Walther DH, Schächinger V, Elsner M, Mach S, Auch-Schwelk W, Zeiher AM. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol. 2000;85:962–8.

  27. 27.

    Kamishirado H, Inoue T, Sakuma M, Tsuda T, Hayashi T, Takayanagi K, Node K. Effects of statins on restenosis after coronary stent implantation. Angiology. 2007;58:55–60.

  28. 28.

    Kang S, Woo HH, Kim K, Lim KM, Noh JY, Lee MY, Bae YM, Bae ON, Chung JH. Dysfunction of vascular smooth muscle and vascular remodeling by simvastatin. Toxicol Sci. 2014;138:446–556.

  29. 29.

    Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:3168–209.

  30. 30.

    Mander S, Kim DH, Thi Nguyen H, Yong HJ, Pahk K, Kim EY, Lee K, Seong JY, Kim WK, Hwang JI. SP-8356, a (1S)-(-)-verbenone derivative, exerts in vitro and in vivo anti-breast cancer effects by inhibiting NF-κB signaling. Sci Rep. 2019;9:6595.

  31. 31.

    Tan I, Butlin M, Liu YY, Ng K, Avolio AP. Heart rate dependence of aortic pulse wave velocity at different arterial pressures in rats. Hypertension. 2012;60:528–33.

  32. 32.

    Daugherty A, Tall AR, Daemen MJAP, Falk E, Fisher EA, García-Cardeña G, Lusis AJ, Owens AP 3rd, Rosenfeld ME, Virmani R, American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on Basic Cardiovascular Sciences. Recommendation on design, execution, and reporting of animal atherosclerosis studies: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2017;37:e131–57.

  33. 33.

    Patching SG. Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand interactions and its potential for drug discovery. Biochim Biophys Acta. 2014;1838:43–55.

  34. 34.

    Rao RS, Miano JM, Olson EN, Seidel CL. The A10 cell line: a model for neonatal, neointimal, or differentiated vascular smooth muscle cells? Cardiovasc Res. 1997;36:118–26.

  35. 35.

    Shin KD, Lee MY, Shin DS, Lee S, Son KH, Koh S, Paik YK, Kwon BM, Han DC. Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation. J Biol Chem. 2005;280:41439–48.

  36. 36.

    Wang C, Jin R, Zhu X, Yan J, Li G. Function of CD147 in atherosclerosis and atherothrombosis. J Cardiovasc Transl Res. 2015;8:59–66.

  37. 37.

    Galis ZS, Johnson C, Godin D, Magid R, Shipley JM, Senior RM, Ivan E. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res. 2002;91:852–9.

  38. 38.

    Li H, Liang J, Castrillon DH, DePinho RA, Olson EN, Liu ZP. FoxO4 regulates tumor necrosis factor alpha-directed smooth muscle cell migration by activating matrix metalloproteinase 9 gene transcription. Mol Cell Biol. 2007;27:2676–86.

  39. 39.

    Ferretti G, Bacchetti T, Banach M, Simental-Mendía LE, Sahebkar A. Impact of statin therapy on plasma MMP-3, MMP-9, and TIMP-1 concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Angiology. 2017;68:850–62.

  40. 40.

    Aikawa M, Sivam PN, Kuro-o M, Kimura K, Nakahara K, Takewaki S, Ueda M, Yamaguchi H, Yazaki Y, Periasamy M, et al. Human smooth muscle myosin heavy chain isoforms as molecular markers for vascular development and atherosclerosis. Circ Res. 1993;73:1000–12.

  41. 41.

    Xu S, Shriver AS, Jagadeesha DK, Chamseddine AH, Szőcs K, Weintraub NL, Griendling KK, Bhalla RC, Miller FJ Jr. Increased expression of Nox1 in neointimal smooth muscle cells promotes activation of matrix metalloproteinase-9. J Vasc Res. 2012;49:242–8.

  42. 42.

    Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet. 2003;361:247–9.

  43. 43.

    Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, et al. Sirolimus eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–23.

  44. 44.

    Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–31.

  45. 45.

    Largerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L, SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009–19.

  46. 46.

    Bonta PI, Pols TW, van Tiel CM, Vos M, Arkenbout EK, Rohlena J, Koch KT, de Maat MP, Tanck MW, de Winter RJ, et al. Nuclear receptor Nurr1 is expressed in an is associated with human restenosis and inhibits vascular lesion formation in mice involving inhibition of smooth muscle cell proliferation and inflammation. Circulation. 2010;121:2023–32.

  47. 47.

    Pi Y, Zhang LL, Li BH, Guo L, Cao XJ, Gao CY, Li JC. Inhibition of reactive oxygen species generation attenuates TLR4-mediated proinflammatory and proliferative phenotype of vascular smooth muscle cells. Lab Invest. 2013;93:880–7.

  48. 48.

    Choi IY, Lim JH, Hwang S, Lee JC, Cho GS, Kim WK. Anti-ischemic and anti-inflammatory activity of (S)-cis-verbenol. Free Radic Res. 2010;44:541–51.

Download references

Acknowledgements

Not applicable.

Funding

This work was supported by a Grant from the Basic Science Research Program [NRF-2015R1A2A01004202, NRF-2018R1A2A2A05018319] through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning, Republic of Korea. This work was also supported by the Technology Innovation Program (10078367, Development of New Drug for Intractable Cardio-Cerebro Vascular Diseases through Inhibition of CD147/EMMPRIN) funded by the Ministry of Trade, Industry & Energy (MOTIE), Republic of Korea.

Author information

Affiliations

  1. Institute for Inflammation Control, Korea University, Seoul, South Korea
    • Kisoo Pahk
    • , Hyojin Noh
    • , Chanmin Joung
    • , Mi Jang
    • , Hwa Young Song
    • , Kihoon Han
    •  & Won-Ki Kim
  2. Department of Neuroscience, Korea University College of Medicine, 126-1, Anam-Dong 5-Ga, Seongbuk-Gu, Seoul, 136-705, South Korea
    • Kisoo Pahk
    • , Hyojin Noh
    • , Chanmin Joung
    • , Mi Jang
    • , Hwa Young Song
    • , Kihoon Han
    •  & Won-Ki Kim
  3. Department of Nuclear Medicine, Korea University Anam Hospital, Seoul, South Korea
    • Kisoo Pahk
    •  & Sungeun Kim
  4. Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
    • Kyung Won Kim
  5. Department of Biomedical Sciences, Korea University College of Medicine, Seoul, South Korea
    • Jong-Ik Hwang
Authors
  1. Search for Kisoo Pahk in:
  2. Search for Hyojin Noh in:
  3. Search for Chanmin Joung in:
  4. Search for Mi Jang in:
  5. Search for Hwa Young Song in:
  6. Search for Kyung Won Kim in:
  7. Search for Kihoon Han in:
  8. Search for Jong-Ik Hwang in:
  9. Search for Sungeun Kim in:
  10. Search for Won-Ki Kim in:

Contributions

KP and WK designed the study. KP, HN, CJ, HYS, KWK, KH, JH, and MJ performed experiments and collected data. KP, HN, KH, JH, SK, and WK analyzed and interpreted the data. KP and WK drafted the manuscript. WK critically revised the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Won-Ki Kim.

Ethics declarations

Ethics approval and consent to participate

All experimental protocols and procedures were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Ethics Committee and the Institutional Animal Care and Use Committee of Korea University College of Medicine (Approval No. KOREA-2016-0041).

Consent for publication

Not applicable.

Competing interests

Shinpoong Pharmaceutical Company recently acquired a license from Korea University to develop SP-8356 as an anti-atherosclerotic drug. The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pahk, K., Noh, H., Joung, C. et al. A novel CD147 inhibitor, SP-8356, reduces neointimal hyperplasia and arterial stiffness in a rat model of partial carotid artery ligation. J Transl Med 17, 274 (2019). https://doi.org/10.1186/s12967-019-2024-y

Download citation

Keywords

  • Atherosclerosis
  • Neointimal hyperplasia
  • Arterial stiffness
  • Vascular smooth muscle cell
  • CD147
  • Matrix metalloproteinase
  • MMP-9

Journal of Translational Medicine

ISSN: 1479-5876

Contact us